These results emphasize the significance of <i>LCN2</i> in driving prostate cancer aggressiveness and provide a foundation for exploring targeted interventions that disrupt <i>LCN2</i>-mediated pathways in advanced disease. This evidence concerns the gene LCN2 and Familial prostate cancer.